Clinical Trial Update: Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on BVAC-C evaluating safety and tolerability in HPV16/18-positive cervical cancer (Phase 1/Phase 2) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Cervical Neoplasms

Drugs mentioned

• BVAC-C (BVAC-C)

Snippet

Sponsor: Cellid Co., Ltd. | Conditions: Uterine Cervical Neoplasms | Phase 1, Phase 2 | Status: COMPLETED